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Abstract The treatment of drug-induced toxic epidermal
necrolysis (TEN) remains unsatisfactory. Intravenous
immunoglobulins (IVIg) and intravenous cyclosporin A
(CsA) have shown some eﬃcacy in short series of pa-
tients. We assessed the eﬀects of IVIg and CsA on TEN
lesional and apparently uninvolved skin using standard
histology and immunohistochemistry. Cutaneous biop-
sies were taken from necrotic and clinically uninvolved
TEN skin at admission (D1) before any treatment, and
after a 5-day treatment (D5). Two IVIg-treated patients
(0.75 g/kg/day), two CsA-treated patients (5 mg/kg/day)
and two control patients only receiving supportive care
were compared. Biopsies were examined by standard
histology and immunohistochemistry using antibodies
directed to CD68 antigen (macrophages), CD45R0
antigen (activated T lymphocytes), Factor XIIIa (dermal
dendrocytes) and the CD95 receptor (apoptosis marker).
The diﬀerent cell densities were evaluated by comput-
erized image analysis. The clinical outcomes with the
diﬀerent treatments were also recorded. There was no
obvious diﬀerence in the duration of hospitalization in
intensive care unit between the three groups but one
patient passed away in each of the IVIg- and CsA-
groups. At D5, no diﬀerences were found between the
three groups in the histological and clinical rate of re-
epithelialization, and in the evolution of T lymphocyte,
macrophage and dendrocyte densities in the epidermis
and dermis. However, the expression of the CD95
receptor was similarly and strongly abated at D5 in the
epidermis of IVIg- and CsA-treated patients, while it
was conversely increased in the two patients under
supportive care only. Such a diﬀerence was found both
in necrotic and uninvolved sites. IVIg and CsA treat-
ments thus appeared to exert no obvious eﬀect on the
inﬂammatory inﬁltrate, but both abated the expression
of the CD95 receptor in the skin of TEN patients. This
eﬀect did not seem suﬃcient to fully reverse the clinical
evolution of the disease. It is inferred that IVIg and CsA
do not completely abate the TEN process.
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Drug-induced toxic epidermal necrolysis (TEN) is a life-
threatening disease characterized by extensive destruc-
tion of the epidermis [5]. To date, no cause other than
drugs has been found in TEN although 5% of the cases
remain ‘‘idiopathic’’ [22]. The mortality rate, which is
higher than 40% in patients with more than 30% skin
detachment is mainly due to septicemia and metabolic
disturbances following the loss of epidermal integrity
[11].
The mechanism leading to massive keratinocyte
death in TEN is thought to be apoptosis [18]. Disregu-
lations in the tumor necrosis factor-a (TNF-a) pathway,
CD95 system (Fas ligand-CD95L, Fas receptor-CD95R)
and calcium homeostasis in the epidermis are likely in-
volved [18]. Indeed, TEN keratinocytes express large
amounts of active CD95L able to induce apoptosis of
CD95R-positive cells. CD95R, which belongs to the
TNF/NGF receptor family is over-expressed in TEN
epidermis.
The TEN initiation phase leading to keratinocyte
apoptosis is followed by an ampliﬁcation phase involv-
ing inﬂammatory cells [18]. An active role has been as-
cribed to T lymphocytes, particularly CD4+ cells in the
dermis and CD8+ cells in the epidermis. In addition,
P. Paquet (&) Æ G. Pie´rard
Department of Dermatopathology, University Hospital of Lie`ge,




E. Jacob Æ P. Damas
Intensive care medicine, burn center, University Hospital of Lie`ge,
4000 Liege, Belgium
J. Pirson
Intensive care medicine, burn center, Brussels Military Hospital,
1120 Brussels, Belgium
Arch Dermatol Res (2005) 297: 266–273
DOI 10.1007/s00403-005-0607-3
L1-protein-enriched macrophages and Factor XIIIa-
positive dendrocytes appear also to play pathogenic
roles in the epidermis and dermis, respectively.
In the past, systemic corticosteroids were used for
targeting the inﬂammatory reaction in TEN [8]. How-
ever, there was no evidence for a beneﬁt in the healing
process, while they worsened the prognosis by increasing
the risk of septicemia [8]. Only a few case reports have
reported other treatment modalities including cyclo-
phosphamide [6], pentoxyﬁlline [23], thalidomide [31]
and cyclosporin A (CsA) [1, 9, 12, 15, 18, 21, 25, 26, 32].
Although T lymphocytes are the main target of CsA, the
drug could also somewhat prevent keratinocyte apop-
tosis in TEN [15]. Some TEN patients have also been
treated with intravenous human immunoglobulins
(IVIg) [2, 10, 14, 19, 20, 24, 28–30]. The rationale for this
treatment was to block CD95R on keratinocytes. The
early promising clinical results of IVIg treatment in TEN
were subsequently challenged [2]. Histological and im-
munohistological assessments of the IVIg eﬀects in TEN
skin have not been studied so far.
We presently report on the modiﬁcations in the
inﬂammatory inﬁltrate (T lymphocytes, macrophages,
type I dendrocytes) and in the epidermal CD95R
expression during IVIg and CsA treatments. Both of
these treatments were administered to two TEN pa-
tients. A comparison was made with supportive care
given to two other TEN patients.
TEN was diagnosed in six patients admitted to the
burn units of the University Hospital of Lie`ge and the
Brussels Military Hospital (Belgium). The diagnosis was
established following previously deﬁned criteria [4]. In
each case, a recent drug intake was disclosed. The salient
characteristics of the patients are listed in Table 2. The
disease duration on admission was recorded since the
ﬁrst day of erythematous rash or mucous membrane
involvement. Our center representing a secondary ref-
erence center, the disease duration on admission was
sometimes quite long. On admission, the patients were
placed on a ﬂuidized bed and beneﬁted from supportive
and antiseptic care measures including daily baths. In
two randomized patients, IVIg (Sandogobuline, Nov-
artis Pharma, Basel, Switzerland) was administered daily
at a dose of 0.75 g/kg body weight for ﬁve consecutive
days. These IVIg batches were not tested for their anti-
Fas activity. In two other randomized patients, intra-
venous CsA (Neoral Sandimmun, Novartis Pharma,
Basel, Switzerland) was administered at a daily dosage
of 5 mg/kg body weight for ﬁve consecutive days. We
retrieved from our ﬁles skin biopsies from two other
patients who had been hospitalized in the mid-nineties,
at a time when IVIg and CsA were not advocated in
TEN. These patients had received supportive care only,
without any drug currently considered active in TEN.
Punch biopsies were performed at admission (D1).
They were taken from early bullous lesions (<24 h), and
from the apparently uninvolved skin at 2 cm outside a
blister. They were formalin-ﬁxed and paraﬃn-embed-
ded. Five days later (D5), two other biopsies were ob-
tained next to the ﬁrst samples, that is, one from an
apparently intact skin area and the other from a previ-
ously altered area.
Slides were stained with hematoxylin and eosin. In
addition, the three-step avidin-biotin method was ap-
plied to a panel of antibodies (Table 1). Appropriate
positive controls (graft versus host reaction, bullous
pemphigoid, staphylococcal scalded skin syndrome) and
negative controls (normal skin) were considered [16].
Computerized image analysis (Leica imaging systems,
Qwin, Cambridge, UK) was used to assess the cell
densities relative to each immunolabeling. Blinded
evaluations were performed by an observer unaware of
the clinical condition and treatment. Five contiguous
representative ﬁelds (·400) located in the central part of
the damaged epidermis were analyzed in each lesion.
The cell densities were expressed as the number of po-
sitive cells per surface unit (10,000 lm2). The anti-
CD95R antibody labeled keratinocytes as well as some
inﬂammatory cells in the epidermis. Image analysis al-
lowed to discriminate among these cell types by only
recording the largest positive cells corresponding to the
keratinocytes.
Re-epithelialization at D5 appeared to be moderately
improved in IVIg and CsA-treated patients compared to
the untreated patients (Table 2). No diﬀerence was
suggested between CsA- and IVIg-treated patients.
However, the small number of patients does not permit
ﬁrm conclusion in terms of re-epithelialization. No dif-
ference in time before hospital discharge was evidenced
between the IVIg- and CsA-treated patients, and the
untreated patients (Table 2). One patient of each of the
IVIg-and CsA-groups died from sepsis.
At D1, subepidermal blisters resulted from complete
epidermal necrosis underlined by a discrete mononuclear
cell inﬁltrate. The clinically uninvolved skin looked
histologically normal. At D5, the aspect of bullous skin
remained similar in three patients (pts 2, 4, 5). A
regenerative epidermis was present in three other pa-
tients (pts 1, 3, 6) without any residual blister. In
these latter patients, a discrete superﬁcial perivascular
lymphoid inﬁltrate underlined the thickened epidermis.
In all six patients, the clinically unaltered skin at D5
Table 1 Panel of monoclonal
(Mo) and polyclonal (Po)
antibodies
Antibody Source Dilution Speciﬁcity
Mo, UCLH1 anti-CD45R0 Dako 1:100 Mature T cells
Po, anti-factor XIIIa BioGenex 1:300 Type I dendrocytes
Mo, anti-CD95 (Fas) Dako 1:25 CD95 receptor
Mo, anti-CD68 Dako 1:50 Lysosomes in reactive
macrophages
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remained histologically normal or showed a discrete
superﬁcial perivascular lymphoid inﬁltrate.
Immunohistochemical results are presented in
Tables 3 and 4. In bullous skin, Factor XIIIa+ den-
drocytes represented the most abundant cell population
in the superﬁcial dermis. Compared to the D1 pre-
treatment status, their number was reduced or remained
similar at D5 in all patients but in patient 6 they were
more numerous. At D1, few CD45R0+ T lymphocytes
and rare CD68+ macrophages were disclosed in the
epidermis and superﬁcial dermis of all patients. These
cell densities decreased or remained similar at D5. The
most prominent diﬀerence between treated TEN pa-
tients and those under supportive care only was found in
the CD95R+ keratinocytes. Their number was greatly
decreased at D5 in IVIg (95.8% and 32.5%) and
CsA-treated patients (37.9% and 67.7%). In con-
trast, they markedly increased (+450% and +92.5%) in
the two patients under supported care (Fig. 1). In the
clinically uninvolved skin, Factor XIIIa+ dendrocytes,
CD45R0+ lymphocytes and CD68+ macrophages
were in a small number in all TEN patients, without any
obvious change in their densities between D1 and D5.
CD95R was expressed on many keratinocytes at D1 in
most of the biopsy specimens. In contrast, this immu-
noreactivity was disclosed in less than 1% of the kerat-
inocytes in other non-TEN diseases. At D5, the number
of CD95R+ keratinocytes moderately increased in
IVIg-treated TEN patients, decreased in CsA-treated
patients and greatly increased in TEN patients under
supportive care only (Fig. 2). In some TEN patients, the
number of CD95+ keratinocytes was greater in the
clinically uninvolved skin than in the corresponding
bullous lesions, both at D1 and D5. However, due to the
small number of TEN patients, no ﬁrm relationship was
found between the clinical course and the densities of
CD95R+ keratinocytes and inﬂammatory cells.
High IVIg dosages were recently used to treat some
TEN patients [2, 10, 14, 19, 20, 24, 28–30]. The rationale
for this treatment relied on the in vitro inhibition ofFasR–
FasL interaction and keratinocytes apoptosis by Ig. This
eﬀect is likely mediated by an anti-CD95R activity rather
than by an interaction with CD95L. In vitro studies have
also shown that high dose Ig inhibit CD95R-mediated
apoptosis of keratinocyte in a dose-dependent relation-
ship [27, 30]. However, the in vitro protective eﬀect is
observed at variable concentrations according to the dif-
ferent IVIg batches available for in vivo usage [20, 27].
This observation points to the diﬃculties in standardizing
IVIg treatment of TEN. Preliminary clinical results about
this treatment remain controversial so far, showing either
improvement [10, 14, 19, 20, 24, 28–30] or worsening [2] in
TEN morbidity and mortality. All the clinical non com-
parative studies reported so far were not supported by
histological examination.
Cyclosporin A was also proposed for reversing TEN
progression [1, 9, 12, 15, 21, 25, 26, 32]. The suppressive
action of CsA primarily targets T-cell functions, and it
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































duces TNF-a secretion by human epidermal keratino-
cytes in vitro [15]. This cytokine is one of the major ones
involved in TEN epidermal destruction. Treatment of
mice with subcutaneously injected CsA was shown to
inhibit TNF-a gene expression by about 70% in the skin
[15]. In addition, the CsA immunosuppressive eﬀect may
partly be mediated by inhibition of the activation of the
FasR–FasL system. In vitro, CsA inhibits the drug-in-
duced expression of CD95R and CD95L-mRNA and
blocks drug-mediated apoptosis of some cell types [7].
Only few TEN cases have been treated with CsA in
uncontrolled studies [1, 9, 12, 21, 25, 26, 32]. Clinical
beneﬁcial eﬀects were generally reported, but not sup-
ported by speciﬁc biological evaluations.
The apoptosis marker CD95R is shown here to be
downregulated in clinically involved TEN skin at
completion of a 5-day IVIg or CsA treatment. CD95R
was moderately increased (IVIg) or decreased (CsA) in
Fig. 1 Computerized image
analysis of the expression of
CD95R in necrotic TEN
epidermis, before treatment
(D1) and after a 5-day
treatment with IVIG (a1, a2) or
CsA (b1, b2) in comparison
with a patient beneﬁting from




the clinically uninvolved skin of TEN patients. In
contrast, in TEN patients under supportive care only,
CD95R was markedly increased at D5 compared to
D1 both in the uninvolved and involved skin. Hence,
the present in vivo ﬁndings are in line with the in
vitro inhibitory eﬀects of IVIg and CsA on the
CD95R-CD95L system. No eﬀect of IVIg or CsA was
evidenced on the densities of the TEN inﬂammatory
cell inﬁltrate. This was surprising for CsA, which
exhibits a potent inhibitory eﬀect on activated T
lymphocytes. However, the inability of CsA to
downregulate some types of cutaneous cell inﬂamma-
tory inﬁltrate was previously noticed, especially in
alopecia areata [13].
Although both IVIg and CsA treatments inhibit the
CD95R-CD95L system, this eﬀect may not be powerful
Fig. 2 Computerized image
analysis of the expression of
CD95R in clinically uninvolved
TEN epidermis, before
treatment (D1) and after a 5-
day treatment with IVIG (d1,
d2) or CsA (e1, e2) in
comparison with a patient
beneﬁting from supportive
measures only (f1, f2). CD95+
keratinocytes appear in blue
271
enough to initiate a clinically relevant improvement in
re-epithelialization. Similarly, these drugs appear to fail
to control TEN morbidity and mortality at least when
major risk factors are present. In our series, one IVIg-
treated patient died from sepsis. She was the oldest of
the patients and she suﬀered from previous kidney
deﬁciency. These factors are two negative predictive
factors for TEN outcome [3]. The administered 0.75 g/
kg/day IVIg dosage was also lower than the newly rec-
ommended dosage (1 g/kg/day) [2, 20, 28]. Indeed,
higher IVIg dosage might have impaired her renal
function, leading to increased morbidity risk [2]. Sepsis
was also the cause of death of one of the CsA-treated
patients. This patient suﬀered from cirrhosis, which is a
major mortality risk factor in TEN.
The densities of the inﬂammatory cell inﬁltrates were
moderate in all TEN patients at D1. Only Factor
XIIIa+ dendrocytes appeared boosted at that time.
This supports the concept considering that the early
phase of the TEN process is probably initiated by the
keratinocytes themselves and the dermal dendrocytes
[18]. The pathomechanisms leading to keratinocyte
destruction are probably multiple and diﬀerent at each
stage of epidermal maturation [17]. The apoptosis pat-
tern may involve the calcium-independent CD95 system
in the deeper epidermal layers and a calcium-dependent
system in the superﬁcial epidermis. The present ﬁndings
suggest that the destruction of keratinocytes is provoked
by simultaneous activation of several apoptosis path-
ways. Blocking CD95R may prevent the apoptosis
progression, but has little eﬀect on the epidermal healing
phase. Indeed, the rate of re-epithelialization induced by
both IVIg and CsA during the early TEN phase did not
appear diﬀerent from patients under supportive care
only as assessed by the clinical outcome and by
microscopy at D5. A regenerating epidermis was dem-
onstrated in one CsA and one IVIg-treated patient, but
also in one patient under supportive care only.
In conclusion, both IVIg (0.75 g/kg/day) and CsA
(5 mg/kg/day) treatments appear to inhibit the apopto-
tic CD95 pathway in TEN patients. This eﬀect might not
be eﬀective enough to improve the early clinical evolu-
tion and prognosis in TEN patients with high-risk fac-
tors.
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